EFG Asset Management North America Corp. Increases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

EFG Asset Management North America Corp. boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 18.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 128,294 shares of the biopharmaceutical company’s stock after buying an additional 19,881 shares during the period. Halozyme Therapeutics makes up approximately 0.8% of EFG Asset Management North America Corp.’s investment portfolio, making the stock its 25th largest holding. EFG Asset Management North America Corp. owned 0.10% of Halozyme Therapeutics worth $6,133,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $29,000. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at $29,000. Smartleaf Asset Management LLC boosted its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $69,000. Finally, Parkside Financial Bank & Trust raised its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 322 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock worth $1,754,451 over the last three months. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Trading Down 1.7 %

HALO stock opened at $64.02 on Tuesday. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00. The business’s 50-day moving average is $58.39 and its 200 day moving average is $54.68. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The stock has a market cap of $7.91 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.